Sinclair Pharma PLC Additional Listing (4681P)

TIDMSPH

RNS Number : 4681P

Sinclair Pharma PLC

17 November 2016

Sinclair Pharma plc

Additional listing

London, 17 November 2016 Sinclair Pharma plc (SPH.L), ("Sinclair" or the "Company") the international aesthetics company, announces that 108,934 new ordinary shares of 1p each (the "New Ordinary Shares") have been issued and allotted pursuant to the vesting of awards and exercise of share options under the Company's 2003 Executive Incentive Plan. 6,748 of these New Ordinary Shares have been issued to Alan Olby, Chief Financial Officer, following the exercise of Replacement Options under the Company's 2003 Executive Incentive Plan.

Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on 22 November 2016 and, when issued, the New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares.

Following admission of the New Ordinary Shares, Sinclair will have 502,198,442 ordinary shares of 1p in issue.

This announcement contains inside information.

For further information please contact:

 
 Sinclair Pharma   Tel: +44 (0) 
  plc               20 7467 6920 
 Chris Spooner 
  Alan Olby 
  Andy Crane 
 
 
 Peel Hunt LLP (NOMAD   Tel: +44 (0) 
  and Broker)            20 7418 8900 
 James Steel 
  Oliver Jackson 
 

Media enquiries

 
 FTI Consulting   Tel: +44 (0) 
                   203 727 1000 
 Ben Atwell 
  Brett Pollard 
 

Notes to Editors:

About Sinclair Pharma plc

Sinclair Pharma plc is an international company operating in the fast growth, high gross margin, global aesthetics market. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. The Company is planning entry to multiple new geographic markets and line extension launches over the next few years. Sinclair has an established sales and marketing presence in the leading EU markets and Brazil, and a network of international distributors. For more information, please visit www.sinclairpharma.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

ALSFMMMMGNKGVZM

(END) Dow Jones Newswires

November 17, 2016 05:36 ET (10:36 GMT)